Hospital
Prime Healthcare Services - Garden City LLC
Prime Healthcare Services - Garden City LLC was paid $31.29M by Medicaid between Jan 2018 and Dec 2024, across 264 billing codes. Its largest line is 99285, emergency room visit (most serious) — 28% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES - GARDEN CITY LLC
GARDEN CITY, MI 48135
GARDEN CITY, MI 48135
33aNPI1043625940assigned 06/30/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$31.29M
24GClaims908,527
24DCodes billed264
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#38 of 86
Median peer was paid$21.55M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 126,479 | $4.13M | |
| 2019 | 127,990 | $3.94M | |
| 2020 | 114,514 | $3.65M | |
| 2021 | 126,474 | $4.34M | |
| 2022 | 148,091 | $5.27M | |
| 2023 | 153,390 | $5.46M | |
| 2024incomplete | 111,589 | $4.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 28% | 28,955 | 27,392 | $8.69M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 36,460 | 34,998 | $6.67M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 49,204 | 46,342 | $6.64M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.7% | 21,881 | 20,580 | $1.77M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 15,966 | 14,887 | $521K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 5,191 | 5,045 | $435K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 5,773 | 5,647 | $427K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 3,257 | 3,183 | $413K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 12,321 | 11,740 | $392K |
| G0378 | Hospital observation service, per hour | 1.2% | 2,449 | 2,157 | $370K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 3,931 | 3,859 | $355K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 4,321 | 3,615 | $347K |
252 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 13,924 | $345K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.0% | 4,996 | $321K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,044 | $305K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,912 | $288K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,604 | $287K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,353 | $271K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 543 | $263K |
| 80061 | Lipid panel | <1% | 2,904 | $244K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,387 | $174K |
| 76801 | <1% | 2,635 | $133K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,094 | $130K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,211 | $102K |
| 87428 | <1% | 5,141 | $96K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,896 | $94K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,609 | $80K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,919 | $73K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,257 | $61K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,667 | $54K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 555 | $49K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,420 | $45K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,483 | $44K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,330 | $44K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 101 | $38K |
| 97161 | <1% | 516 | $35K | |
| 93971 | <1% | 751 | $35K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,474 | $28K |
| 86900 | <1% | 4,645 | $27K | |
| 58558 | <1% | 18 | $26K | |
| 93976 | <1% | 608 | $26K | |
| 10060 | <1% | 319 | $25K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 395 | $23K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,458 | $23K |
| 0012A | <1% | 599 | $22K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,480 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,849 | $21K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,546 | $19K |
| 59025 | Fetal non-stress test | <1% | 221 | $18K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 727 | $17K |
| 80053 | Comprehensive metabolic panel | <1% | 16,214 | $16K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,430 | $16K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,598 | $15K |
| 0011A | <1% | 531 | $15K | |
| 97014 | <1% | 1,992 | $14K | |
| 82947 | <1% | 1,351 | $14K | |
| 86769 | <1% | 804 | $13K | |
| 97035 | <1% | 2,112 | $12K | |
| 84702 | <1% | 5,456 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,598 | $9K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 1,062 | $8K |
| 73630 | <1% | 2,153 | $8K | |
| 72131 | <1% | 242 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,123 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,446 | $8K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 252 | $7K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 180 | $7K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,698 | $7K |
| 70486 | <1% | 575 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,123 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 49,314 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26,186 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,248 | $6K |
| 72100 | <1% | 898 | $6K | |
| 84439 | <1% | 1,917 | $5K | |
| 76642 | <1% | 143 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,543 | $4K |
| 29505 | <1% | 62 | $4K | |
| 74018 | <1% | 1,460 | $4K | |
| 29515 | <1% | 64 | $4K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 17 | $4K |
| 85027 | <1% | 4,846 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,202 | $4K |
| 73030 | <1% | 1,732 | $4K | |
| 73610 | <1% | 1,907 | $3K | |
| 83735 | <1% | 8,872 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 243 | $3K |
| 73562 | <1% | 1,720 | $3K | |
| 87070 | <1% | 1,583 | $3K | |
| 87653 | <1% | 266 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 37 | $3K |
| 73130 | <1% | 2,541 | $3K | |
| 82607 | <1% | 360 | $2K | |
| 93970 | <1% | 25 | $2K | |
| 87340 | <1% | 533 | $2K | |
| 85730 | <1% | 9,796 | $2K | |
| 76770 | <1% | 38 | $2K | |
| 80055 | <1% | 123 | $2K | |
| 86850 | <1% | 3,304 | $2K | |
| 80076 | <1% | 7,292 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 25 | $2K |
| 86592 | <1% | 790 | $2K | |
| 83880 | <1% | 1,474 | $1K | |
| 87088 | <1% | 3,298 | $1K | |
| 87186 | <1% | 2,912 | $1K | |
| 84550 | <1% | 1,001 | $1K | |
| 87081 | <1% | 3,604 | $1K | |
| 86762 | <1% | 218 | $1K | |
| 83690 | <1% | 12,766 | $1K | |
| 83001 | <1% | 234 | $1K | |
| 85610 | <1% | 10,469 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,682 | $1K |
| 83540 | <1% | 408 | $1K | |
| 83550 | <1% | 277 | $1K | |
| 73110 | <1% | 708 | $1K | |
| 86901 | <1% | 4,626 | $1K | |
| 73120 | <1% | 406 | $996.01 | |
| 84460 | <1% | 654 | $979.40 | |
| 87077 | <1% | 2,685 | $975.46 | |
| 93975 | <1% | 12 | $974.17 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 49 | $973.54 |
| 81001 | <1% | 19,754 | $956.25 | |
| 84450 | <1% | 655 | $955.52 | |
| 83021 | <1% | 257 | $936.99 | |
| 76000 | <1% | 13 | $935.12 | |
| 74019 | <1% | 1,469 | $928.24 | |
| 70496 | <1% | 29 | $928.04 | |
| 82105 | <1% | 217 | $873.10 | |
| 83615 | <1% | 711 | $832.71 | |
| 82565 | <1% | 811 | $769.10 | |
| 0002A | <1% | 27 | $698.99 | |
| 82150 | <1% | 1,713 | $688.79 | |
| 72110 | <1% | 45 | $666.31 | |
| 72170 | <1% | 522 | $661.99 | |
| 84520 | <1% | 726 | $600.70 | |
| 82950 | <1% | 373 | $597.59 | |
| 82728 | <1% | 208 | $591.71 | |
| 73502 | <1% | 123 | $530.25 | |
| 86140 | <1% | 1,502 | $509.06 | |
| 12001 | <1% | 1,133 | $503.75 | |
| 82550 | <1% | 3,684 | $500.28 | |
| 0001A | <1% | 32 | $494.45 | |
| 85007 | <1% | 2,017 | $452.56 | |
| 86696 | <1% | 94 | $451.92 | |
| 84100 | <1% | 6,157 | $438.05 | |
| 87147 | <1% | 626 | $435.62 | |
| 94664 | <1% | 1,039 | $411.58 | |
| 81003 | <1% | 12,265 | $404.67 | |
| 97116 | <1% | 32 | $401.31 | |
| 86803 | <1% | 49 | $359.88 | |
| 73564 | <1% | 217 | $357.84 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 27 | $355.08 |
| 84484 | <1% | 12,802 | $354.33 | |
| 86703 | <1% | 85 | $342.69 | |
| 96367 | <1% | 48 | $338.85 | |
| 86787 | <1% | 114 | $336.17 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 5,208 | $306.34 |
| 86695 | <1% | 93 | $303.58 | |
| 73590 | <1% | 233 | $274.89 | |
| 85652 | <1% | 962 | $264.89 | |
| 81025 | <1% | 22,550 | $253.16 | |
| 85660 | <1% | 249 | $252.11 | |
| 70498 | <1% | 13 | $242.26 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,049 | $238.40 |
| 82677 | <1% | 54 | $232.20 | |
| 84153 | <1% | 25 | $206.68 | |
| 74022 | <1% | 746 | $202.53 | |
| 82140 | <1% | 39 | $198.00 | |
| 80051 | <1% | 196 | $194.51 | |
| 83605 | <1% | 6,470 | $194.46 | |
| 73560 | <1% | 27 | $192.94 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 23,131 | $188.70 |
| 73620 | <1% | 226 | $179.13 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,002 | $175.69 |
| 73090 | <1% | 475 | $171.03 | |
| 87040 | <1% | 2,803 | $162.50 | |
| 90715 | <1% | 2,295 | $153.53 | |
| 86336 | <1% | 54 | $149.70 | |
| 85379 | <1% | 2,020 | $137.93 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 12 | $131.65 |
| 82962 | <1% | 3,888 | $131.01 | |
| 96376 | <1% | 2,514 | $115.63 | |
| 86694 | <1% | 43 | $106.17 | |
| 88312 | <1% | 39 | $93.10 | |
| 83002 | <1% | 31 | $92.80 | |
| 84156 | <1% | 159 | $88.10 | |
| 82570 | <1% | 98 | $79.38 | |
| 87205 | <1% | 96 | $77.38 | |
| 71101 | <1% | 61 | $59.64 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,593 | $57.86 |
| J1815 | Injection, insulin, per 5 units | <1% | 461 | $55.86 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,773 | $50.61 |
| 73070 | <1% | 156 | $48.33 | |
| 73100 | <1% | 13 | $48.14 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,103 | $44.95 |
| 73080 | <1% | 28 | $42.94 | |
| 82043 | <1% | 12 | $38.96 | |
| 82977 | <1% | 13 | $36.24 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,148 | $33.91 |
| 73600 | <1% | 64 | $31.62 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,303 | $25.53 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 17 | $20.09 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,897 | $17.68 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,269 | $16.13 |
| 84145 | <1% | 469 | $13.33 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,986 | $10.75 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,634 | $10.46 |
| J3490 | Unclassified drugs | <1% | 7,933 | $10.05 |
| 87807 | <1% | 1,103 | $10.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,461 | $9.43 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,640 | $7.63 |
| 94799 | <1% | 98 | $6.56 | |
| 82670 | <1% | 13 | $5.08 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,648 | $3.88 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,692 | $3.75 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,253 | $3.35 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 849 | $1.27 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 42 | $0.38 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,366 | $0.30 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,941 | $0.25 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,834 | $0.20 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 864 | $0.02 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 279 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 3,984 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 3,238 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 59 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 1,960 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,986 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 412 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,214 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 633 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 62 | $0.00 |
| 94760 | 0% | 115 | $0.00 | |
| 12002 | 0% | 130 | $0.00 | |
| 91301 | 0% | 1,136 | $0.00 | |
| 73552 | 0% | 13 | $0.00 | |
| 99156 | 0% | 51 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 73 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 26 | $0.00 |
| C1769 | Guide wire | 0% | 116 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 13 | $0.00 |
| 88304 | 0% | 13 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 13 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 14 | $0.00 |
| 29125 | 0% | 622 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 453 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 705 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 180 | $0.00 |
| 12011 | 0% | 139 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 16 | $0.00 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 232 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 258 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 38 | $0.00 |
| 99157 | 0% | 39 | $0.00 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 62 | $0.00 |
| 82805 | 0% | 40 | $0.00 | |
| 82009 | 0% | 56 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 29 | $0.00 |
| 91300 | 0% | 59 | $0.00 | |
| 76999 | 0% | 46 | $0.00 | |
| 70360 | 0% | 16 | $0.00 | |
| 76775 | 0% | 28 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 31 | $0.00 |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUTCHER, GINA (REGIONAL CFO)
Parent organizationPRIME HEALTHCARE HOLDINGS INC
| Provider | Location | Paid |
|---|---|---|
| VHS Sinai-Grace Hospital INC | Detroit, MI | $96.77M |
| VHS Sinai-Grace Hospital INC | Detroit, MI | $1.47M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.